Melanoma Clinical Trials in Portland

Showing 141-160 of 161 trials

Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery

NCT01989559

This pilot clinical trial studies booster vaccination in preventing disease recurrence in previously vaccinated patients with melanoma that has been removed by surgery. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer.

Recurrent MelanomaStage IA Skin MelanomaStage IB Skin Melanoma+7 more

National Cancer Institute (NCI)30 participantsStarted Oct 2002

Portland, Oregon, United States

COMPLETEDPhase 2< 1 mile

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

NCT00623766

To assess the response of melanoma with brain metastases to ipilimumab treatment while maintaining acceptable tolerability.

Melanoma

Bristol-Myers Squibb99 participantsStarted Jul 2008

Scottsdale, Arizona, United States • Duarte, California, United States • Los Angeles, California, United States +11 more locations

Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

Melanoma Trials in Other Cities

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma

S9804: Vinorelbine in Treating Patients With Stage IV Melanoma

S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma

Long-term Data Collection for Subjects in MDX-010 Studies

Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

Study of CP-675,206 in Refractory Melanoma

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma

Phase II Trial of Allovectin-7® for Metastatic Melanoma

Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer

Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma

SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

Other Conditions in Portland